Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05972473 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Aug 15, 2023 to Sep 21, 2023 Trial status: Recruiting to Active, Not Recruiting · Study site revisedv3 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Primary endpoint revised · Site details revisedv2 Show 2 more changesShow less
    • Primary endpoint revised
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Trial Details
NCT Number NCT05972473
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Neovascular Age-related Macular Degeneration
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov